fbpx

EMCM partners with CritiTech to develop coated tissue grafts

EMCM, a Leader Biomedical Group company, partnered with CritiTech, a rapidly growing drug development company, to develop tissue grafts coated with a variety of pharmaceuticals to be used (especially) in revision surgeries. The grafts will provide long-lasting microbial control and accelerate the healing process.

The grafts will be produced using Leader Biomedical’s eCOO® Technology, which relies on the use of supercritical carbon dioxide to clean and sterilise tissue.

For more information, please see the original article on the EMCM website.